{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:43:20Z","timestamp":1792784600059,"version":"4.5.0"},"reference-count":139,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Austrian MPS Society"},{"DOI":"10.13039\/100013927","name":"National MPS Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013927","id-type":"DOI","asserted-by":"crossref"}]},{"name":"International Morquio Organization"},{"DOI":"10.13039\/100000009","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P20GM103464"],"award-info":[{"award-number":["P20GM103464"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.ymgme.2014.12.001","type":"journal-article","created":{"date-parts":[[2014,12,8]],"date-time":"2014-12-08T19:31:01Z","timestamp":1418067061000},"page":"94-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"title":["Therapies for the bone in mucopolysaccharidoses"],"prefix":"10.1016","volume":"114","author":[{"given":"Shunji","family":"Tomatsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos J.","family":"Alm\u00e9ciga-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana M.","family":"Monta\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromasa","family":"Yabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akemi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vu Chi","family":"Dung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francyne","family":"Kubaski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Sawamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Mackenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji E.","family":"Orii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A.","family":"Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Sly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Orii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2014.12.001_bb0005","series-title":"The metabolic and molecular bases of inherited disease","first-page":"3421","article-title":"The mucopolysaccharidoses","author":"Neufeld","year":"2001"},{"key":"10.1016\/j.ymgme.2014.12.001_bb0010","first-page":"2091","article-title":"Impairment of body growth in mucopolysaccharidoses","volume":"1","author":"Tomatsu","year":"2012"},{"key":"10.1016\/j.ymgme.2014.12.001_bb0015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ymgmr.2013.10.001","article-title":"Growth charts for patients with Hunter syndrome","volume":"1","author":"Patel","year":"2014","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0020","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2174\/138920111795542615","article-title":"Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment","volume":"12","author":"Tomatsu","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0025","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ppul.21246","article-title":"Characteristics of impulse oscillometry and thoracoabdominal motion in children with thoracic cage disorders","volume":"45","author":"Rodriguez","year":"2010","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0030","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1460-9592.2012.03904.x","article-title":"Anesthetic care and perioperative complications of children with Morquio syndrome","volume":"22","author":"Theroux","year":"2012","journal-title":"Paediatr. Anaesth."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0035","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","article-title":"Enzyme-replacement therapy in mucopolysaccharidosis I","volume":"344","author":"Kakkis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0040","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0045","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1651-2227.2002.tb03118.x","article-title":"Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report","volume":"91","author":"Muenzer","year":"2002","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0050","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s10545-014-9715-6","article-title":"Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study","volume":"37","author":"Hendriksz","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0055","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jpeds.2004.03.018","article-title":"Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux\u2013Lamy syndrome)","volume":"144","author":"Harmatz","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0060","doi-asserted-by":"crossref","first-page":"e681","DOI":"10.1542\/peds.2004-1023","volume":"115","author":"Harmatz","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2014.12.001_bb0065","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","volume":"148","author":"Harmatz","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0070","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ymgme.2008.04.001","article-title":"Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase","volume":"94","author":"Harmatz","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0075","first-page":"1","article-title":"A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type I","volume":"10","author":"Connock","year":"2006","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0080","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2165\/00003495-200767180-00005","article-title":"Treatment of lysosomal storage disorders: progress with enzyme replacement therapy","volume":"67","author":"Rohrbach","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.ymgme.2014.12.001_bb0085","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/nbt1030","article-title":"Characterizing biological products and assessing comparability following manufacturing changes","volume":"22","author":"Chirino","year":"2004","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0090","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2165\/00003088-200645100-00002","article-title":"Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs","volume":"45","author":"Parveen","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0095","first-page":"2868","article-title":"Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I","volume":"118","author":"Dickson","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0100","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/mt.2010.32","article-title":"Enhancement of drug delivery: enzyme replacement therapy for murine Morquio A syndrome","volume":"18","author":"Tomatsu","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0105","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ymgme.2012.07.002","article-title":"Long circulating enzyme replacement therapy rescues bone pathology in mucopolysaccharidosis VII murine model","volume":"107","author":"Rowan","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2013.12.255","article-title":"Enzyme replacement therapy in newborn mucopolysaccharidosis IVA mice: early treatment rescues bone lesions?","author":"Tomatsu","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0115","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1023\/A:1005525931994","article-title":"Long-term follow-up following bone marrow transplantation for Hunter disease","volume":"22","author":"Vellodi","year":"1999","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0120","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.bbmt.2008.01.009","article-title":"The clinical outcome of Hurler syndrome after stem cell transplantation","volume":"14","author":"Aldenhoven","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0125","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1302\/0301-620X.76B6.7983131","article-title":"Bone-marrow transplantation in Hurler's syndrome. Effect on skeletal development","volume":"76","author":"Field","year":"1994","journal-title":"J. Bone Joint Surg. (Br.)"},{"issue":"Suppl. 2","key":"10.1016\/j.ymgme.2014.12.001_bb0130","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1038\/bmt.2008.62","article-title":"The controversial and changing role of haematopoietic cell transplantation for lysosomal storage disorders: an update","volume":"41","author":"Rovelli","year":"2008","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0135","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood-2012-09-455238","article-title":"Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning","volume":"121","author":"Boelens","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2014.12.001_bb0140","first-page":"676","article-title":"Treatment of murine mucopolysaccharidosis type VII by syngeneic bone marrow transplantation in neonates","volume":"68","author":"Sands","year":"1993","journal-title":"Lab. Investig."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0145","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.V97.5.1498","article-title":"Nonablative neonatal marrow transplantation attenuates functional and physical defects of beta-glucuronidase deficiency","volume":"97","author":"Soper","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2014.12.001_bb0150","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/8904_2012_169","article-title":"Neonatal bone marrow transplantation in MPS IIIA mice","volume":"8","author":"Lau","year":"2013","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0155","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ymgmr.2014.04.001","article-title":"Impact of enzyme replacement therapy and hematopoietic stem cell therapy on growth in patients with Hunter syndrome","volume":"1","author":"Patel","year":"2014","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0160","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/jgm.581","article-title":"Gene therapy for lysosomal storage diseases: the lessons and promise of animal models","volume":"6","author":"Ellinwood","year":"2004","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0165","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2174\/156652306776359522","article-title":"Cell and gene-based therapies for the lysosomal storage diseases","volume":"6","author":"Hodges","year":"2006","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0170","first-page":"65","article-title":"Current and emerging treatments and surgical interventions for Morquio A Syndrome: a review","volume":"2012","author":"Tomatsu","year":"2012","journal-title":"Res. Rep. Endocr. Disord."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0175","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1111\/j.1742-4658.2010.07769.x","article-title":"Adeno-associated virus gene transfer in Morquio A disease: effect of promoters and sulfatase-modifying factor 1","volume":"277","author":"Alm\u00e9ciga-D\u00edaz","year":"2010","journal-title":"FEBS J."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0180","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1073\/pnas.0912937107","article-title":"Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses","volume":"107","author":"Simonaro","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0022447","article-title":"Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI","volume":"6","author":"Eliyahu","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2014.12.001_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0054459","article-title":"Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses","volume":"8","author":"Schuchman","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2014.12.001_bb0195","doi-asserted-by":"crossref","first-page":"e 100882","DOI":"10.1371\/journal.pone.0100882","article-title":"Dose responsive effects of subcutaneous pentosan polysulfate injection in mucopolysaccharidosis type VI rats and comparison to oral treatment","volume":"9","author":"Frohbergh","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2014.12.001_bb0200","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1651-2227.1995.tb13640.x","article-title":"The presenting features of mucopolysaccharidosis type IH (Hurler syndrome)","volume":"84","author":"Cleary","year":"1995","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0205","doi-asserted-by":"crossref","first-page":"F205","DOI":"10.1136\/fn.84.3.F205","article-title":"Detection of inborn errors of metabolism in the newborn","volume":"84","author":"Chakrapani","year":"2001","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0210","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/j.cca.2012.07.011","article-title":"First pilot newborn screening for four lysosomal storage diseases in an Italian region: identification and analysis of a putative causative mutation in the GBA gene","volume":"413","author":"Paciotti","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2014.12.001_bb0215","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jpeds.2013.01.031","article-title":"Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry","volume":"163","author":"Scott","year":"2013","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-8-147","article-title":"A pilot newborn screening program for Mucopolysaccharidosis type I in Taiwan","volume":"8","author":"Lin","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0225","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ymgme.2013.06.007","article-title":"Newborn screening and diagnosis of mucopolysaccharidoses","volume":"110","author":"Tomatsu","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0230","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1651-2227.2009.01134.x","article-title":"Sacral dimple: incidental findings from newborn evaluation. Mucopolysaccharidosis IVA disease","volume":"98","author":"Ohashi","year":"2009","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0235","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/pd.1970121207","article-title":"Fetal presentation of Morquio disease type A","volume":"12","author":"Beck","year":"1992","journal-title":"Prenat. Diagn."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0240","first-page":"122","article-title":"Prenatal pathology in mucopolysaccharidoses: a comparison with postnatal cases","volume":"2","author":"Martin","year":"1983","journal-title":"Clin. Neuropathol."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0245","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1093\/hmg\/ddg366","article-title":"Mouse model of N-acetylgalactosamine-6-sulfate sulfatase deficiency (Galns\u2212\/\u2212) produced by targeted disruption of the gene defective in Morquio A disease","volume":"12","author":"Tomatsu","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0250","first-page":"207","article-title":"A murine model of mucopolysaccharidosis VII. Gross and microscopic findings in beta-glucuronidase-deficient mice","volume":"136","author":"Vogler","year":"1990","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0255","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10545-012-9522-x","article-title":"Assessment of bone dysplasia by micro-CT and glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIIA, IVA, and VII","volume":"36","author":"Rowan","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0260","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy","volume":"167","author":"Wraith","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0265","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ymgme.2009.08.006","article-title":"Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II)","volume":"99","author":"Okuyama","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0270","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/hmg\/ddm353","article-title":"Enzyme replacement therapy in a murine model of Morquio A syndrome","volume":"17","author":"Tomatsu","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.3001380","article-title":"Replacing the enzyme alpha-l-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I","volume":"2","author":"Dierenfeld","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0280","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1172\/JCI119208","article-title":"Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI","volume":"99","author":"Crawley","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0285","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1096-7192(03)00007-6","article-title":"Replacement therapy in mucopolysaccharidosis type VI: advantages of early onset of therapy","volume":"78","author":"Auclair","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0290","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ymgme.2013.03.005","article-title":"Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice","volume":"109","author":"Baldo","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0295","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1172\/JCI117237","article-title":"Enzyme replacement therapy for murine mucopolysaccharidosis type VII","volume":"93","author":"Sands","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0300","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1203\/00006450-199606000-00019","article-title":"Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival","volume":"39","author":"Vogler","year":"1996","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0305","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1023\/A:1005423222927","article-title":"Murine mucopolysaccharidosis type VII: the impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease","volume":"21","author":"Vogler","year":"1998","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0310","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10545-010-9059-9","article-title":"Efficacy of recombinant human alpha-l-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients","volume":"33","author":"Tylki-Szymanska","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0315","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10545-013-9654-7","article-title":"Galsulfase (Naglazyme\u00ae) therapy in infants with mucopolysaccharidosis VI","volume":"37","author":"Harmatz","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0320","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ymgme.2011.08.029","article-title":"Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI","volume":"104","author":"Furujo","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0325","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1399-0004.2009.01324.x","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI from 8weeks of age\u2014a sibling control study","volume":"77","author":"McGill","year":"2010","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0330","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1542\/peds.2009-1728","article-title":"Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up","volume":"125","author":"Gabrielli","year":"2010","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2014.12.001_bb0335","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1111\/j.1651-2227.2011.02385.x","article-title":"Enzyme replacement therapy for mucopolysaccharidosis II from 3months of age: a 3-year follow-up","volume":"101","author":"Tylki-Szymanska","year":"2012","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0340","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ymgme.2012.12.010","article-title":"Effects of idursulfase enzyme replacement therapy for mucopolysaccharidosis type II when started in early infancy: comparison in two siblings","volume":"108","author":"Tajima","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0345","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1073\/pnas.0712147105","article-title":"Chemically modified beta-glucuronidase crosses blood\u2013brain barrier and clears neuronal storage in murine mucopolysaccharidosis VII","volume":"105","author":"Grubb","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0350","doi-asserted-by":"crossref","first-page":"19430","DOI":"10.1016\/S0021-9258(19)77651-0","article-title":"The primary structure of a cell-binding bone sialoprotein","volume":"263","author":"Oldberg","year":"1988","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0355","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1359\/jbmr.2000.15.5.936","article-title":"Selective drug delivery system to bone: small peptide (Asp)6 conjugation","volume":"15","author":"Kasugai","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0360","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1042\/bj2740513","article-title":"Biosysnthesis of bone proteins [SPP-1 (secreted phosphoprotein-1, osteopontin), BSP (bone sialoprotein) and SPARC (osteonectin) in association with mineralized-tissue formation by fetal-rat calvarian cells in culture","volume":"274","author":"Nagata","year":"1991","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0365","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/03008208909002412","article-title":"The nature and significance of osteopontin","volume":"23","author":"Butler","year":"1989","journal-title":"Connect. Tissue Res."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0370","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/10611869808995866","article-title":"Osteotropic drug delivery system (ODDS) based on biphosphonic prodrug. I.V. effects of osteotropic estradiol on bone mineral density and uterine weight in ovariectomized rats","volume":"5","author":"Fujisaki","year":"1998","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0375","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/10611860108997922","article-title":"Novel drug delivery system to bone using acidic oligopeptide: pharmacokinetic characteristics and pharmacological potential","volume":"9","author":"Sekido","year":"2001","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0380","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1210\/endo.142.3.8024","article-title":"Selective delivery of estradiol to bone by aspartic acid oligopeptide and its effects on ovariectomized mice","volume":"142","author":"Yokogawa","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.ymgme.2014.12.001_bb0385","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ymgme.2006.02.012","article-title":"Targeted drug delivery to bone: characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptide","volume":"88","author":"Nishioka","year":"2006","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0390","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJMoa1106173","article-title":"Enzyme-replacement therapy in life-threatening hypophosphatasia","volume":"8","author":"Whyte","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0395","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10545-013-9646-7","article-title":"Enzyme replacement therapy on hypophosphatasia mouse model","volume":"37","author":"Oikawa","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0400","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1359\/jbmr.071213","article-title":"Enzyme replacement therapy for murine hypophosphatasia","volume":"23","author":"Mill\u00e1n","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0405","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ymgme.2008.01.007","article-title":"Acidic amino acid tag enhances response to enzyme replacement in mucopolysaccharidosis type VII mice","volume":"94","author":"Monta\u00f1o","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0410","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s12519-008-0031-9","article-title":"Long-term follow-up of a girl with Maroteaux\u2013Lamy syndrome after bone marrow transplantation","volume":"4","author":"Wang","year":"2008","journal-title":"World J. Pediatr."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0415","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10545-005-0258-8","article-title":"Trends in haematopoietic cell transplantation for inborn errors of metabolism","volume":"29","author":"Boelens","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0420","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jpeds.2007.04.054","article-title":"Hematopoietic cell therapy for metabolic disease","volume":"151","author":"Orchard","year":"2007","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0425","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/sj.bmt.1705934","article-title":"Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome","volume":"41","author":"Tolar","year":"2008","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0430","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/sj.bmt.1705586","article-title":"Analysis of factors affecting development of carpal tunnel syndrome in patients with Hurler syndrome after hematopoietic cell transplantation","volume":"39","author":"Khanna","year":"2007","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0435","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/8904_2012_175","article-title":"Prevalence and development of orthopaedic symptoms in the Dutch Hurler patient population after haematopoietic stem cell transplantation","volume":"9","author":"Stoop","year":"2013","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0440","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/adc.76.2.92","article-title":"Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres","volume":"76","author":"Vellodi","year":"1997","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0445","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/sj.bmt.1704105","article-title":"Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources","volume":"31","author":"Souillet","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0450","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/01241398-199611000-00006","article-title":"Hip dysplasia in Hurler's syndrome: orthopaedic management after bone marrow transplantation","volume":"16","author":"Masterson","year":"1996","journal-title":"J. Pediatr. Orthop."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0455","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/BPO.0b013e3181649e25","article-title":"Mobility in Hurler syndrome","volume":"28","author":"Taylor","year":"2008","journal-title":"J. Pediatr. Orthop."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0460","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/01241398-200401000-00019","article-title":"Musculoskeletal manifestations of hurler syndrome: long-term follow-up after bone marrow transplantation","volume":"24","author":"Weisstein","year":"2004","journal-title":"J. Pediatr. Orthop."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0465","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1136\/ard.2008.095315","article-title":"Musculoskeletal manifestations of lysosomal storage disorders","volume":"68","author":"Aldenhoven","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0470","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-8-155","article-title":"Treatment of hip dysplasia in patients with mucopolysaccharidosis type I after hematopoietic stem cell transplantation: results of an international consensus procedure","volume":"8","author":"Langereis","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0475","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1023\/A:1005447232027","article-title":"Bone marrow transplantation for Maroteaux\u2013Lamy syndrome (MPS VI): long-term follow-up","volume":"22","author":"Herskhovitz","year":"1999","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0480","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.pediatrneurol.2003.09.003","article-title":"The status of hematopoietic stem cell transplantation in lysosomal storage disease","volume":"29","author":"Malatack","year":"2003","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00439-006-0280-4","article-title":"New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy","volume":"121","author":"Beck","year":"2007","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0490","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ymgme.2010.09.010","article-title":"Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI","volume":"102","author":"Turbeville","year":"2011","journal-title":"Mol. Genet. Metab."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2014.12.001_bb0495","first-page":"141","article-title":"Morquio A syndrome: diagnosis and current and future therapies","volume":"12","author":"Tomatsu","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0500","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ymgmr.2013.11.002","article-title":"Long-term therapeutic efficacy of allogenic bone marrow transplantation in a patient with mucopolysaccharidosis IVA","volume":"1","author":"Chinen","year":"2014","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0505","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jpeds.2008.11.041","article-title":"Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17years","volume":"154","author":"Guffon","year":"2009","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0510","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ymgme.2009.05.006","article-title":"Localized donor cells in brain of a Hunter disease patient after cord blood stem cell transplantation","volume":"98","author":"Araya","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0515","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ymgme.2012.09.004","article-title":"Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan","volume":"107","author":"Tanaka","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0520","article-title":"Activities of Daily Living in patients with Hunter syndrome: impact of enzyme replacement therapy and hematopoietic stem cell transplantation","author":"Tanjuakio","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0525","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.649.649","article-title":"Neonatal bone marrow transplantation prevents bone pathology in a mouse model of mucopolysaccharidosis type I","author":"Pievani","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2014.12.001_bb0530","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1056\/NEJMoa032613","article-title":"Cord-blood transplants from unrelated donors in patients with Hurler's syndrome","volume":"350","author":"Staba","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0535","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1182\/asheducation-2005.1.377","article-title":"Umbilical cord blood transplantation: a new alternative option","author":"Tse","year":"2005","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.ymgme.2014.12.001_bb0540","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.seminhematol.2009.10.008","article-title":"Transplant outcomes in mucopolysaccharidoses","volume":"47","author":"Prasad","year":"2010","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0545","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/01.GIM.0000154299.22120.6A","article-title":"Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome","volume":"7","author":"Grewal","year":"2005","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0550","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.2174\/138161211797247578","article-title":"Gene therapy for lysosomal storage diseases: progress, challenges and future prospects","volume":"17","author":"Seregin","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0555","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1517\/14712598.7.9.1333","article-title":"Gene therapy for mucopolysaccharidosis","volume":"7","author":"Ponder","year":"2007","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0560","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1517\/21678707.2013.846853","article-title":"Therapies of mucopolysaccharidosis IVA (Morquio A syndrome)","volume":"1","author":"Tomatsu","year":"2013","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.ymgme.2014.12.001_bb0570","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1194\/jlr.R047175","article-title":"Gene therapy for the neurological manifestations in lysosomal storage disorders","volume":"55","author":"Cheng","year":"2014","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0575","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/mt.2008.119","article-title":"Targeting of the CNS in MPS-IH using a nonviral transferrin-alpha-l-iduronidase fusion gene product","volume":"16","author":"Osborn","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0580","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/mt.2010.249","article-title":"Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of alpha-l-iduronidase in mice with mucopolysaccharidosis type I","volume":"19","author":"Osborn","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0585","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/jgm.1028","article-title":"Prolonged expression of a lysosomal enzyme in mouse liver after Sleeping Beauty transposon-mediated gene delivery: implications for non-viral gene therapy of mucopolysaccharidoses","volume":"9","author":"Aronovich","year":"2007","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0590","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/mt.2009.87","article-title":"Systemic correction of storage disease in MPS I NOD\/SCID mice using the sleeping beauty transposon system","volume":"17","author":"Aronovich","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0595","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/sj.mt.6300201","article-title":"Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy","volume":"15","author":"Traas","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0600","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/jgm.1229","article-title":"Improved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice","volume":"10","author":"Herati","year":"2008","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0605","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ymgme.2008.07.003","article-title":"Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy","volume":"95","author":"Herati","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0610","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1182\/blood-2010-04-278234","article-title":"Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model","volume":"9","author":"Visigalli","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2014.12.001_bb0615","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2010.265","article-title":"Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes","volume":"19","author":"Ellinwood","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0620","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.nbd.2011.02.015","article-title":"Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I","volume":"43","author":"Wolf","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0625","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1089\/104303401753204571","article-title":"Various cells retrovirally transduced with N-acetylgalactosoamine-6-sulfate sulfatase correct Morquio skin fibroblasts in vitro","volume":"12","author":"Toietta","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0630","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.ymgme.2008.11.006","article-title":"Adeno-associated virus mediated gene therapy in a murine model of Morquio syndrome type A","volume":"96","author":"Alm\u00e9ciga-D\u00edaz","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0635","first-page":"221","article-title":"Contribuci\u00f3n colombiana al conocimiento de la enfermedad de Morquio","volume":"34","author":"Alm\u00e9ciga-D\u00edaz","year":"2012","journal-title":"Medicina (Mex)"},{"key":"10.1016\/j.ymgme.2014.12.001_bb0640","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.ymgme.2012.11.022","article-title":"New viral vectors for Morquio syndrome type A gene therapy","volume":"108","author":"Alm\u00e9ciga-D\u00edaz","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0645","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/mt.2010.257","article-title":"Long-term amelioration of feline Mucopolysaccharidosis VI after AAV-mediated liver gene transfer","volume":"19","author":"Cotugno","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0650","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/hum.2012.179","article-title":"Gene therapy for mucopolysaccharidosis type VI is effective in cats without pre-existing immunity to AAV8","volume":"24","author":"Ferla","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0655","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/mt.2012.9","article-title":"Neonatal gene therapy with a gamma retroviral vector in mucopolysaccharidosis VI cats","volume":"20","author":"Ponder","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0660","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ymgme.2012.03.013","article-title":"Effect of neonatal gene therapy on lumbar spine disease in mucopolysaccharidosis VII dogs","volume":"107","author":"Smith","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0665","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ymgme.2013.03.013","article-title":"The effect of neonatal gene therapy on skeletal manifestations in mucopolysaccharidosis VII dogs after a decade","volume":"109","author":"Xing","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0670","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ymgme.2012.03.022","article-title":"Skeletal response to lentiviral mediated gene therapy in a mouse model of MPS VII","volume":"106","author":"Macsai","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0675","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/mt.2012.100","article-title":"Sialic acid deposition impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse model of lysosomal storage disease","volume":"20","author":"Chen","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0680","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/gt.2009.52","article-title":"Long-term AAV vector gene and protein expression in mouse brain from a small pan-cellular promoter is similar to neural cell promoters","volume":"16","author":"Husain","year":"2009","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0685","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ymgme.2013.04.009","article-title":"Pathogenesis of Morquio A syndrome: an autopsied case reveals systemic storage disorder","volume":"109","author":"Yasuda","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0690","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6904-10-7","article-title":"Sodium pentosan polysulfate resulted in cartilage improvement in knee osteoarthritis\u2013an open clinical trial","volume":"10","author":"Kumagai","year":"2010","journal-title":"BMC Clin. Pharmacol."},{"key":"10.1016\/j.ymgme.2014.12.001_bb0695","doi-asserted-by":"crossref","first-page":"e54459","DOI":"10.1371\/journal.pone.0054459","article-title":"Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses","volume":"8","author":"Schuchman","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymgme.2014.12.001_bb0700","doi-asserted-by":"crossref","first-page":"e100882","DOI":"10.1371\/journal.pone.0100882","article-title":"Dose responsive effects of subcutaneous pentosan polysulfate injection in mucopolysaccharidosis type VI rats and comparison to oral treatment","volume":"9","author":"Frohbergh","year":"2014","journal-title":"PLoS One."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719214003813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719214003813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T22:34:58Z","timestamp":1650753298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719214003813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":139,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S1096719214003813"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2014.12.001","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapies for the bone in mucopolysaccharidoses","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2014.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}